Search
Metoxepin
go.drugbank.com/drugs/DB21433ExperimentalMetoxepin is a small molecule drug. The usage of the INN stem '-oxepin' in the name indicates that Metoxepin is a tricyclic compound. Metoxepin has a monoisotopic molecular weight of 322.17 Da.
Rizedisben
go.drugbank.com/drugs/DB21610InvestigationalRizedisben is a small molecule drug. Rizedisben is under investigation in clinical trial NCT04983862 (Fluorescent Imaging of Nerves with Illuminare-1 During Surgery). … Rizedisben has a monoisotopic molecular weight of 519.22 Da.
Synonyms: Illuminare-1Davelizomib
go.drugbank.com/drugs/DB21660ExperimentalDavelizomib is a small molecule drug. The usage of the INN stem '-zomib' in the name indicates that Davelizomib is a proteasome inhibitor. Davelizomib has a monoisotopic molecular weight of 481.18 Da.
Certociclib
go.drugbank.com/drugs/DB21736InvestigationalCertociclib is a small molecule drug. Certociclib is under investigation in clinical trial NCT05252416 ((VELA) Study of BLU-222 in Advanced Solid Tumors). … Certociclib has a monoisotopic molecular weight of 365.14 Da.
Whole Blood
go.drugbank.com/drugs/DB28492ExperimentalFresh Whole Blood is a biologic drug. Fresh Whole Blood is under investigation in clinical trial NCT03737669 (Mirasol Evaluation of Reduction in Infections Trial).
ONO-4915
go.drugbank.com/drugs/DB33978ExperimentalONO-4915 is a small molecule drug. ONO-4915 is under investigation in clinical trial NCT07823790 (ONO-4915 in Patients With Primary Sjogren's Disease).
Rivoglitazone
go.drugbank.com/drugs/DB09200InvestigationalRivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsFosinoprilat
go.drugbank.com/drugs/DB14207ExperimentalFosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.
AUM-601
go.drugbank.com/drugs/DB17382ExperimentalAUM-601 is a highly selective pan-TRK(tropomyosin receptor kinase). It is currently being investigated in clinical trials for the treatment of cancer.
VAD-044
go.drugbank.com/drugs/DB17697InvestigationalVAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]
Synonyms: 6-(4-((1S,3S)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one